DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application is being examined under the pre-AIA first to invent provisions.
Specification
The disclosure is objected to because of the following informalities: Applicant is requested to amend the first paragraph of the specification to indicate that related applications 18/383,005 and 17/459,563 have been abandoned.
Appropriate correction is required.
The lengthy specification has not been checked to the extent necessary to determine the presence of all possible minor errors. Applicant’s cooperation is requested in correcting any errors of which applicant may become aware in the specification.
Claim Objections
Claims 13, 14, 16, 21, and 30 are objected to because of the following informalities:
In claim 13, lines 1-2: “an appropriate connection” should apparently read --the appropriate connection--.
In claim 14, lines 1-2: “an appropriate connection” should apparently read --the appropriate connection--.
In claim 16, lines 1-2: “an appropriate connection” should apparently read --the appropriate connection--.
In claim 21, line 5: the dash should apparently be a colon.
In claim 21, line 28: there should apparently be a semicolon or a comma following “the battery.”
In claim 30, line 1: “the therapeutic signal” should apparently read --the stored therapeutic signal--.
In claim 30, line 9: “the therapeutic signal” should apparently read --the stored therapeutic signal--.
Appropriate correction is required.
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 10-18 and 21-30 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Claim 10 recites the limitation “about 1 Hz and 22 Hz” in line 12. The term “about” in is a relative term which renders the claim indefinite. The term is not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. The metes and bounds of the claimed range are not readily determinable.
Claim 10 also recites the limitation "the signal generator" in line 15. There is insufficient antecedent basis for this limitation in the claim; this should apparently read --the signal generator portion--.
Claim 10 also recites the limitation "the magnetic signal" in line 22. There is insufficient antecedent basis for this limitation in the claim; this should apparently read --the magnetic therapeutic signal--. It is noted that this limitation also appears in claim 13 (line 3), which may need to be amended in kind.
Claim 12 recites the limitation "the stored electromagnetic signal" in line 2. There is insufficient antecedent basis for this limitation in the claim.
Claim 15 recites the limitations "the absence" in line 15 and “the other generated signal” in lines 15-16. There is insufficient antecedent basis for these limitations in the claim.
Claims 11-18 are rejected by virtue of their dependence upon claim 10.
Claim 21 recites the limitation "the one or more ailments" in lines 15-16. There is insufficient antecedent basis for this limitation in the claim.
Claim 21 also recites the limitation "the processor" in line 29. It is not clear which of the potentially multiple “at least one processor” is being referred to.
Claim 25 recites the limitation "the signal generator portion" in line 3. There is insufficient antecedent basis for this limitation in the claim; only a signal generator has been previously recited.
Claim 30 recites the limitation "the absence" in line 10. There is insufficient antecedent basis for this limitation in the claim.
Claim 30 also recites the limitation “source radiation from the sample” in line 19. It is not clear if this is meant to refer to the previously recited “sample source radiation” or to be separate radiation.
Claims 22-30 are rejected by virtue of their dependence upon at least one rejected base claim.
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
Claims 10-18 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-8, 10, and 11 of U.S. Patent No. 10,046,172. Although the claims at issue are not identical, they are not patentably distinct from each other because they recite essentially identical limitations such that they would not meet a one-way test for distinctness. Claim 1 of the issued patent includes all of the limitations of present claim 10, except for the recitation in the preamble of “to maintain or reduce a volume of malignant tumors.” It is submitted that this is an intended result of the claimed method that the method of claim 1 of the issued patent would be able to achieve. Claims 2-4 of the issued patent correspond to present claims 11-13, while claims 5 and 6 of the issued patent correspond to present claim 14, claims 7 and 8 of the issued patent correspond to present claims 15 and 16, and claims 10 and 11 of the issued patent correspond to present claims 17 and 18, respectively.
Claims 21-30 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-10 of U.S. Patent No. 11,103,721. Although the claims at issue are not identical, they are not patentably distinct from each other because they recite essentially identical limitations such that they would not meet a one-way test for distinctness. Claim 1 of the issued patent includes all of the limitations of present claim 21, except for the recitation in the preamble of “to provide treatment for cancer.” It is submitted that this is an intended result/use of the claimed apparatus that the apparatus of claim 1 of the issued patent would be able to achieve. Claims 2-10 of the issued patent correspond to present claims 22-30, respectively.
Allowable Subject Matter
Claims 10-18 and 21-30 would be allowable if rewritten or amended to overcome the rejection(s) under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), 2nd paragraph, set forth in this Office action and if the double patenting rejections set forth in this Office action are overcome.
The following is a statement of reasons for the indication of allowable subject matter: while encryption/decryption of stored signals is known in the prior art of record (e.g., U.S. Pub. Nos. 2012/0143285 A1, 2008/0069738 A1, 2004/0181115 A1), along with disabling application of a signal after a certain time interval (e.g., U.S. No. 7,933,654 B2), none of the prior art of record teaches or reasonably suggests a method for providing a magnetic therapeutic signal that includes checking for an appropriate connection between the electromagnetic transducer portion and the signal generator portion, unsecuring such a stored therapeutic signal, and disabling the signal generator when the timer reaches a predetermined value to prohibit reuse of the stored signal, in combination with the other recited steps; nor such an apparatus including an electromagnetic portion and a signal generator, wherein the signal generator includes processor-executable instructions for disabling the signal generator by erasing such a stored therapeutic signal when the timer reaches a predetermined value to prohibit reuse of the stored signal, in combination with the other recited components.
Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to THADDEUS B COX whose telephone number is (571)270-5132. The examiner can normally be reached M-F 9am-6pm.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jason M. Sims can be reached at (571)272-7540. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/THADDEUS B COX/Primary Examiner, Art Unit 3791